Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. ETF
  3. ANIX
ANIX logo

ANIX

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewTechnicalNews
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

ANIX News

Anixa Secures Korean Patent for Breast Cancer Vaccine

2d agoPRnewswire

Anixa Biosciences Secures Patent Allowance in South Korea

2d agoseekingalpha

Anixa Biosciences to Host 2026 Annual Stockholders Meeting

Mar 02 2026PRnewswire

Anixa Biosciences to Host 2026 Annual Stockholders Meeting

Mar 02 2026Newsfilter

Anixa Biosciences Updates on Ovarian Cancer CAR-T Trial Outcomes

Feb 09 2026Benzinga

Anixa Biosciences' CAR-T Therapy Receives Naming Approval

Feb 02 2026PRnewswire

Anixa Biosciences CAR-T Therapy Receives Naming Approval

Feb 02 2026Newsfilter

Anixa Secures Mexican Patent for Breast Cancer Vaccine

Jan 27 2026PRnewswire

Anixa Biosciences Declines Following Phase 1 Results for Breast Cancer Vaccine

Dec 12 2025SeekingAlpha

Anixa Biosciences' Phase 1 Study Shows Breast Cancer Vaccine is Safe and Well Tolerated

Dec 12 2025NASDAQ.COM

Anixa Biosciences Vaccine Trial Achieves 74% Immune Response in Phase 1 Study

Dec 11 2025PRnewswire

Anixa Biosciences Reports 74% Immune Response in Phase 1 Breast Cancer Vaccine Trial

Dec 11 2025Newsfilter

Anixa Biosciences CEO to Join Investor Fireside Chat on Dec 15, 2025

Dec 10 2025PRnewswire

Anixa Biosciences CEO to Discuss Breast Cancer Vaccine Data on December 15

Dec 10 2025Newsfilter

Anixa Biosciences Receives WHO Approval for International Non-Proprietary Name of CAR-T Therapy, Signifying Major Step Towards Global Recognition and Future Market Launch

Nov 17 2025Newsfilter

Water Tower Research Releases Statement on Technical Issues During Anixa Biosciences Fireside Chat

Nov 12 2025Newsfilter